Skip to main content

Table 1 Sequence of clinical events

From: Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia

Event sequence

WBC (×109)

Eosinophils in PB (%, AEC)

Eosinophils in BM (%)

Blasts in BM (%)

Diagnosis

Intervention

Disease status

Initial presentation

44.6

1, 0.45

1

7

CMML-1

SGI-110

Refractory

After 2 months

65.1

9, 5.8

5

4

CMML-1

SGI-110

Progression

After 1 month

126

11, 13.8

16

12

Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and PDGFRA rearrangement

Fludarabine + Cytarabine

Progression

After 1 month

6.4

1, 0.06

1

26

AML with PDGFRA rearrangement

Imatinib (with Idarubicin + Cutarabine)

Remission

  1. WBC: white blood cells, PB: peripheral blood, AEC: absolute eosinophil count, BM: bone marrow, CMML: chronic myelomonocytic leukemia, AML: acute myeloid leukemia.